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Contraceptives to Adolescent and Young Women in a Public Health Setting 
 
In an urban, publicly funded women’s health and family planning clinic, 56% of 
pregnancies were reported to be unintended.  The clinic director decided to address this 
problem by focusing on providers’ contraceptive prescribing habits; especially 
contraceptive prescribing for women aged 15-25.  The purpose of the evidence-based 
practice improvement (EBPI) project was to increase provider disclosure about longer-
acting reversible contraception (intrauterine and implantable methods known as “LARC” 
methods).  The goal of the EBPI project was to increase the percentage of contraceptive 
prescriptions that are LARC methods for women aged 15-25 years.  The clinical question 
guiding the EBPI project was “Among healthcare providers in a public health clinic, how 
does utilization of an evidence-based toolkit for providers, staff, and patients about long 
acting reversible contraception (LARC), compared to no intervention, affect the 
percentage of LARC prescriptions among all contraceptive prescriptions written for 
women ages 15-25 over three months?”  The intervention was a toolkit utilizing 
components created and utilized by The Contraceptive Choice Project that had 
demonstrated increased LARC prescribing and utilization in a similar Mid-western city.  
The toolkit addressed specific prescribing barriers that were identified through an internal 




framework guided the EBPI project.  This framework included rapid cycling in which the 
intervention was regularly evaluated and adjusted with the goal of eventually realizing an 
intervention that would sustain the goal of increasing LARC prescribing for women ages 
15-25.  The anticipated outcome was an increase in the percent of long-acting reversible 
contraceptives out of all contraceptives prescribed.  Because the patient population was 
small overall, the EBPI project team decided to collect data on women of all ages, but to 
separately calculate the EBPI project outcomes for women ages 15-25.  The outcome was 
an increase (from 6% to 20%) in LARC prescribing for patients’ ages 15-25, but a 
decrease in LARC prescribing for patients older than age 26 (from 23% to 12.5%).  
Changes in providers’ opinions were also measured with before and after surveys.  
Findings from these surveys included an increase in consistency of language to describe 
LARC methods, and recognition of the availability of LARC methods at the site.  
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I.  INTRODUCTION 
Despite the existence of effective contraceptive methods, half of all pregnancies in 
the United States are unintended and 82% of pregnancies in 15-19 year old women are 
unintended (Centers for Disease Control and Prevention [CDC], 2011a).  In 2008, the last 
year for which there is published data, 55% of all pregnancies in Ohio were unintended 
(Kost & Henshaw, 2013).  At a public health clinic serving low-income women in a 
medium-sized, Mid-western city, 56% of all pregnancies were reported to be unintended 
(Clinic Site Director, personal communication November 22, 2013).  Unintended 
pregnancies are associated with adverse maternal outcomes and neonates born as the 
result of unintended pregnancies are more likely to be born prematurely and to have 
negative physical and mental health effects (Guttmacher, 2013).  Furthermore, there is a 
cost burden related to unintended pregnancies.  Taxpayer costs related to the medical care 
associated with unintended pregnancy ranges between $9.6 and $12.6 billion per year 
(Monea & Thomas, 2011).  In addition, low-income women ages 15-25 have the highest 
rates of unintended pregnancy (Finer & Zolna, 2014).  When unintended pregnancy 
occurs in adolescent women or women of lower socioeconomic status, unintended 
pregnancies have the potential to further compromise opportunities for education and 
employment.   
Contraceptive Availability and Efficacy 
 There are existing methods of contraception that are more than 99% effective at 
preventing pregnancy.  These include sterilization, the contraceptive implant, and
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intrauterine contraception (IUC or IUD)  (Hatcher et al., 2008).  However, at the time of 
unintended pregnancy as many as 45.4% of Ohio women report not using contraception 
(CDC, 2011a).  Contraception can prevent pregnancy by altering a woman’s fertility 
and/or creating a barrier between sperm and egg.  When any hormonal method is used 
correctly and the woman does not experience gastrointestinal illness or medication 
interactions, the rate of unintended pregnancy can be reduced to less than 0.05% per year.  
In literature addressing contraceptive efficacy, the annual rate of unintended pregnancy 
by method type is referred to as the method failure rate (Hatcher et al., 2008).  Method 
failure is further classified into perfect use failure rate and typical use failure rate.  Perfect 
use means that the woman or couple used the method exactly as prescribed without 
delayed or missed doses, gastrointestinal illness, or interaction from another medication.  
Typical use failure rates account for how the method is typically used in the context of a 
woman’s life (Hatcher, et al., 2008). 
Method Types 
Short acting reversible contraceptive methods include the oral contraceptive pill 
(OCP), patch, and vaginal ring.  These methods require a woman to adhere to a dosing 
schedule on a daily, weekly, or monthly basis.  An injectable method, depo 
medroxyprogesterone acetate (DMPA), requires an office visit for intramuscular injection 
every 11-15 weeks, and can take longer to reverse than other contraceptive methods 
(CDC, 2010).  Long-acting reversible contraceptive methods (LARC), (intrauterine 
methods and the single rod implant) on the other hand, require rare action on the part of 
the user and their contraceptive effect ends with removal of the device.  At the national 




contraceptive users reporting this as their primary contraceptive method (The United 
States Department of Health and Human Services [DHHS], 2011) (See Figure 1). 
Unfortunately, OCPs are not the most effective method of preventing pregnancy.  
 
Figure 1. Percent of Female Contraceptive Use in the U.S. by Method Type. Percentages 
per United States Department of Health and Human Services, 2011.  
 
Method Efficacy 
As displayed in Table 1, LARC methods have superior efficacy with typical use, 
are more likely to be continued at one year, and can be cost effective when the initial cost 
is divided by years of use and simply by preventing the costs associated with unintended 
pregnancy.  Because LARC methods eliminate user error as a component of efficacy, the 
three LARC methods discussed here all have typical use efficacy rates of greater than 
99% whereas DMPA has a typical use efficacy rate of 94%, the OCP, the patch, and the 
ring have rates of 92%, and the male condom has a rate of 85% (see Table 1) (CDC, 
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first choice method of contraception as evidenced by statements from the American College of 
Obstetricians and Gynecologists (ACOG), The World Health Organization (WHO), and The 
Centers for Disease Control and Prevention (CDC) (ACOG, 2011; CDC, 2010).  Limiting the 
availability of some methods of contraception is discouraged.  As a national benchmark, Healthy 
People 2020 initiative 3.1 has established the goal that all Title X funded clinics provide a full 
range of contraceptive methods approved by the Food and Drug Administration (FDA) (DHHS, 
2012).  Title X clinics are federally funded programs dedicated to providing family planning 
services to all Americans. 
Cost 
When viewed solely from a cost perspective, family-planning services save four dollars 
in pregnancy related care for every dollar spent on contraception (DHHS, 2012).  Cost to the 
consumer is an evolving issue as the Affordable Care Act (ACA) purports to cover all 
prescription contraceptive methods at no cost to the consumer (DHHS, 2014a).  The reality of 
implementing this coverage, however, remains unclear.  Further, consideration of cost needs to 
include long-term cost to the user and to society.  The cost figures presented here do not address 
the long-term financial sequelae for individuals and society that result from lost wages, deferred 
education, and the perpetuation of poverty that can result from unintended pregnancy.  
Background specific to the study site 
To better understand the baseline prescribing patterns at the Midwestern urban public 
health clinic where the EBPI project was implemented, all contraceptive prescriptions given for 
women of all ages for the month of October 2013 (the most recent available baseline data at the 




revealed that OCPs were the most common contraceptive prescribed with 56% of patients using 
the OCP method (See Fig. 2 and 3).  The clinic exceeded the national average for LARC method 
prescribing with LARC methods composing of 23% of all contraceptive prescriptions.  However, 
women aged 15-25 were only prescribed LARC methods 6% of the time.  According to the clinic 
director these numbers were consistent with overall contraceptive prescribing trends in the clinic 
for the year prior to data analysis (Clinic Site Director, personal communication, November 21, 
2013).  While it is laudable that this clinic’s overall LARC prescribing exceeds the national 
average, there remains significant room for improvement when only 6% of the clinic’s 
contraceptive patients aged 15-25 are using the most efficacious methods and the site maintains 
an unintended pregnancy rate of 56%.  
Survey of Similar Sites 
The clinic site director wanted to address the 56% unintended pregnancy rate at the 
clinic.  Because LARC methods have demonstrated to be the most effective methods of 
contraception (Hatcher et al., 2008) the site director decided to attempt to lower the unintended 
pregnancy rate by working first to increase the rate of LARC prescribing to patients of the clinic.  
To this end, the site director partnered with the director of a community organization called 
Council on Healthy Mothers and Babies (COHMAB) to discuss collaboration on a project to 
reduce the rate of unintended pregnancy in the clinic site that may then be generalizable to other 
public health settings in the community (Clinic Site Director, personal communication, January 
13, 2013).  The clinic site director and COHMAB director decided to conduct an assessment of 
barriers to LARC prescribing in similar sites by administering a survey to groups of patients and 





Figure 2. October 2013 Contraceptive Prescriptions at EBPI project site for patients age 15-25 





Figure 3. October 2013 Contraceptive Prescriptions at EBPI site for patients of all ages.  LARC-
long acting reversible contraceptive  
Method Type Ages 15-25
LARC 6%
Other 94%





The two site directors asked a doctor of nursing practice (DNP) student, who became the 
EBPI project leader, to assist them in this process.  Therefore, a team was formed for 
conducting an internal quality improvement project that consisted of the site director, the 
COHMAB director, and the DNP student.  First the team developed two surveys, one for 
healthcare providers and one for patients.  The questions in each survey were not 
validated; they came from the expert opinion and practical experience of members of the 
team (See Appendix A).  The goal of conducting the surveys were to determine the 
accuracy of knowledge about LARC methods among providers and patients of public 
health facilities in the area. 
The COHMAB director posted provider surveys in an online anonymous format 
to provider members of COHMAB.  Notably, providers of the site where the doctoral 
EBPI project eventually took place did not participate in this initial survey.  COHMAB 
member providers are those that provide women’s healthcare in local public health 
settings. Fourteen providers were invited to participate and 5 surveys were completed.  
Patient surveys were administered by paper and pencil to members of a group for new 
mothers that were run by the COHMAB director.  Four surveys were completed and 
returned.  Data collection took place in the Spring of 2013.  It is not known whether the 
four women who participated in the new mothers’ group were ever patients of the site 
where the EBPI project eventually took place.  Overall only four patient responses and 
five provider responses were collected.  Responses were then compiled and presented to 
the COHMAB board by the COHMAB director and the DNP student (See Appendix B). 




Although the sample size was small, the themes that emerged were informative.  
Patients thought of condoms as their primary contraceptive method and looked to their 
providers for contraceptive advice.  Even more revealing were the provider responses to 
the question “Are there certain patients for whom you are more or less likely to discuss 
long acting reversible methods?”  Answers to this question revealed lack of knowledge 
about the appropriateness of IUD use among young and/or nulliparous women, bleeding 
expectations with IUDs, and biases against patients’ follow up care and questions 
associated with the use of LARC methods.  After these findings were presented to the 
COHMAB board by the COHMAB director and the DNP student, attendees at the 
COHMAB meeting noted that women looked to their providers for guidance regarding 
contraceptive method choice and that providers had lingering misperceptions and biases 
about LARCs in general and especially about never-pregnant adolescents as candidates 
for LARC methods.  After analysis of these limited findings, ultimately, the team charged 
the current EBPI project leader (the DNP student) with the task of conducting a review of 
literature to identify methods to improving the rate of LARC prescribing. 
Guiding Framework 
A framework was selected in order to guide literature appraisal and 
implementation for a change in practice.  The guiding framework was the Evidence-
Based Practice Improvement (EBPI) model (Levin, et al., 2010).  This framework was 
chosen because it incorporates both evidence-based practice and quality improvement, or 
program improvement methods.  Evidence-based practice (EBP) integrates research 
evidence with clinical expertise and patient preference (Melynk and Fineout-Overholt, 




framework for defining and focusing a clinical question” (Levin, et al., 2010, p. 117).  
Quality Improvement (QI) is an ongoing process that uses rapid cycles to continually 
appraise, alter, and effectively sustain an improvement (DHHS, 2014b).  The EBPI model 
was developed as a way to incorporate the systematic evidence gathering and appraisal of 
evidence with a practical approach to application and sustainability of an effort that is 
afforded by QI (Levin, et al., 2010).  
Multiple QI models for rapid small tests of change were identified.  The 
implementation model incorporated in the EBPI framework is “Plan, do, study, act” or 
“PDSA”.  Plan, do, study, act is a formative evaluation process that includes frequent 
feedback from stakeholders and the use of “small tests of change” before employing a 
change on a large scale (Levin, et al., 2010, p. 123).  This framework was an excellent fit 
for the EBPI project because literature on the topic was collected and appraised using 
evidence-based practice tools (Melnyk & Fineout-Overholt, 2011) and the information 
obtained was combined with internal findings from geographically similar sites to create 
a site-specific EBPI project.  The PDSA cycles were an ideal component of the 
framework because they allowed the site providers and staff to experiment with 
modifying components of the intervention to find the best fit for the specific site.  Step 
one of the EBPI model is describing the clinical problem.  The clinical problem the site 
chose to address was the need to reduce the current rate of unintended pregnancy (56%) 
reported by patients at the clinic by increasing prescribing of LARC methods. 
PICOT Question 
Initially, the clinical problem was formatted into a searchable question using the 




Outcome, Time) is a format for asking clinical questions that can help to focus a literature 
search (Cochrane Collaboration, 2006).  The question that guided the literature search 
was “Among healthcare providers in a public health clinic, how does an intervention to 
increase provider disclosure of long acting reversible contraception (LARC), compared to 
no intervention, affect the percentage of LARC prescriptions among all contraceptive 
prescriptions written for women ages 15-25 over three months?”  Based on the literature 
review a subsequent PICOT question was developed.   
Purpose and Goals 
 The purpose of the EBPI project was to increase prescriber disclosure of LARC 
methods as the most effective method of contraception.  The goal of the EBPI project was 
to increase the percentage of contraceptive prescriptions that were LARC methods.  This 
was an evidence-based practice change project.  An evidence-based practice process was 





Search Strategies and Results  
Initial database searches using the terms “advanced practice nurse,” and 
“adolescent” along with terminology about contraception produced very limited results.  
Therefore, in order to gather as much information as possible the term “Long acting 
contracep*” was entered in the Cochrane, CINAHL, and PubMed databases to capture 
the key phrases “long acting contraceptive” and “long acting contraception”.  Using this 
term over 300 articles were identified. Thirty-six of those were deemed relevant from the 
abstract and read in detail.  Of the thirty-six, five were formally evaluated and kept in the 
evidence synthesis (See Table 2).  Additional hand gathering of articles was done after 
reviewing articles referenced in the articles found in the key word searches.  The search 
terms were saved in PubMed and periodic updates from PubMed provided additional 
articles that were utilized in the evaluation and synthesis of the most relevant literature.  
These more recent articles did not suggest any changes beyond what was gathered 
initially, they simply reinforced the need to change provider mindsets so that LARC is 
seen as the best method of contraception for most women.  
Inclusion and Exclusion Criteria 
Initially the search was limited to articles published in the last 10 years, with 
particular attention to articles published in the last five to six years.  While multiple 
articles from international sites were reviewed, ultimately, articles focusing on the United 





Literature Search  
Search 
Date 
Keyword Database # listed # reviewed # used 
 
3/7/13 Long acting 
contraceptive 
Cochrane 7 7 0 
3/7/13 Long acting 
contracep* 





























available in the United States.  In summary, recent articles with larger sample sizes, 
examining provider counseling in relation to contraceptive devices available in the 
United States were kept in the final synthesis.  Articles examining the cost effectiveness 
of LARC methods were also retained.  In addition, two sets of guidelines were reviewed 
and included in the collection of external evidence (See Table 3).  
Article Appraisal 
 Articles were appraised using a technique called “Rapid critical appraisal” as 
defined by Melnyk and Fineout-Overholt (2011).  This method includes evaluating each 
article for level of evidence (described below), how the study was conducted (including 
design, method, and possible confounding variables), and usefulness of study findings to 
practice.  Because the question addressed here was an intervention question, the evidence 
was ranked (or leveled) as follows: Level 1; systematic reviews or meta-analyses of 
randomized controlled trials, Level 2; randomized controlled trials; Level 3 
nonrandomized controlled trials; Level 4 cohort or case-control studies; Level 5 Meta-





Characteristics of Studies Included in Practice Recommendation 
Citation Rationale for Inclusion 
Mestad, R., Secura, G., Allsworth, J.E., Madden, 
T., Zhao, Q., & Peipert, J.F. (2011). Acceptance 
of long-acting reversible contraceptive methods 
by adolescent participants in the contraceptive 
CHOICE project. 
Large sample size, specifically 
interested in adolescent 
acceptance of, and choice among 
LARC methods 
Tyler, et. al. (2012). Health care provider attitudes 
and practices related to intrauterine devices for 
nulliparous women 
Found healthcare provider 
attitudes to be a barrier to LARC 
provision 
Deans, E. & Grimes, D. (2009). Intrauterine 
devices for adolescents: A systematic review 
Only broad systematic review 
located, addressed provider 
counseling as a variable 
Kavanaugh, (2013). Meeting the contraceptive 
needs of teens and young adults: Youth friendly 
and long-acting reversible contraceptive services 
in U.S. family planning facilities. 
 
Teen and young adult population,  
Large sample size 
Provider counseling as a variable 
Lewis, (2013). Intrauterine contraception: Impact 
of provider training on participant knowledge and 
provision. 
 
Recent article,  
Clinician training as variable 
ACOG (2011) Guideline Addresses LARC candidate 
selection 
 
USMEC (2010) Guideline Addresses LARC candidate 
selection 
 
studies, and Level 7 expert opinion (Melnyk & Fineout-Overholt, 2011, p. 32).  
Clinical Practice Guidelines 
 Two sets of guidelines were reviewed: The American College of Obstetricians 
and Gynecologists (ACOG) practice bulletin on LARC (2011) and the U.S. Medical 
Eligibility for Contraceptive Use (USMEC) (CDC, 2010).  While neither set of guidelines 
gave guidance specifically on provider disclosure, they did address the necessity of a shift 
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in provider understanding about LARC usage and LARC candidate selection.  Both 
documents were reviewed using the rapid critical appraisal tool for guidelines (Melnyk & 
Fineout-Overholt, 2011) (See Appendix C).  The Committee on Practice Bulletins-
Gynecology developed the ACOG guideline with assistance from two LARC experts.  
Committee membership is not explicitly stated, so it is impossible to determine conflicts 
of interest, but it is plausible that the committee was composed of ACOG members who 
are all physicians and is, therefore, not an interdisciplinary group.  The funding source 
was also not specifically disclosed, but may be from membership dues.  While the 
recommendations made reference to numerous previous studies, no systematic method of 
appraising the quality of the relevant literature was reported.  It was not stated whether 
the guideline had been subjected to peer review.  The guideline recommendations were 
clinically relevant and feasible, may lead to an increase in LARC prescribing and 
provision, and outcomes could be measured by measuring changes in LARC prescribing. 
The USMEC was adapted from the World Health Organization (WHO) Medical 
Eligibility for Contraceptive Use (4th ed.) by the CDC’s Division of Reproductive Health.  
The panel that adapted the WHO guidelines for specific U.S. use included “Eight key 
partners and U.S. family planning experts” (CDC, 2010, p. 2).  Only minor adaptations 
were made to account for issues such as availability of certain methods in the U.S.  The 
panel conducted a systematic literature review for each recommendation considered for 
adaptation using the United States Preventive Services Taskforce (USPSTF) system to 
grade the evidence (USPSTF, 2014).  Next the panel analyzed each systematic review.  
After this, a larger meeting of 31 contraceptive experts from different specialties 
convened to comment on the evidence presented.  The guideline did not make explicit 
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recommendations, but graded each contraceptive method on a safety scale for a number 
of demographic and health criteria.  The recommendations are clinically relevant and 
assist in making direct patient care decisions about contraceptive eligibility.  The 
recommendations are practical and economically feasible.  The recommendations could 
trigger a variation from standard care particularly with regard to increased provision of 
LARC methods due to a better understanding of patient eligibility for these methods.  
Outcomes of this change in practice could then be measured.  The ultimate 
recommendation was to consider LARC as first choice methods for all women unless an 
individual woman is deemed medically ineligible for a LARC method. 
Findings from the Literature Review 
Nationally, only 3.6 % of adolescents use IUDs (which are a LARC method) (DHHS, 
2011).  However, in one large study when education was provided and initial cost was 
removed as a barrier, 60% of adolescent women chose LARC methods (Mestad, et al., 
2011).  Further, Tyler and colleagues (2012) found that barriers to LARC provision 
included; misconceptions about LARC associated with being a family medicine 
specialist, not being trained in IUD insertion, and non-availability of IUDs on-site.  Other 
authors found that provider training was critical to increasing LARC provision and that 
there is a positive association between rate of LARC provision and provider training in 
“youth-friendly” contraceptive services (Deans & Grimes, 2009; Kavanaugh, et al., 2013; 
Lewis, Darney, & Theil de Bocanegra, 2013; Mested, et al., 2011; Tyler et. al., 2012).  
(See Table 4 for evaluation of the evidence retrieved from the literature search).  The 
evidence was assigned a level and rated for quality and usefulness to practice. 
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with IUD insertion 
training and on-site 
device availability 
were also more likely 
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clinicians are less 
likely than WH 
specialists to have 
LARC. Increase in 
LARC provision 
after training may be 
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Study did not control 
for other variables.  
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sending a clinician to 
training were used in 
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claims specific to the 
clinician who 
attended the training.  
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The evidence for the intervention used in this EBPI project was comprised of 
cohort studies and expert opinion.  Expert opinion generalized the scientific 
understanding of the appropriateness of LARC methods as first line contraception to 
adolescent and nulliparous women based on understanding of reproductive anatomy and 
background literature establishing the safety and efficacy of LARC methods (Kavenaugh, 
et al., 2013) (See Table 5).  Findings from published literature suggest that barriers to 
increasing LARC prescribing exist.  Barriers include the initial higher cost, patient 
misconceptions, and provider misconceptions, which can inhibit disclosure of all methods 
(Cope, Yano, Lee, & Washington, 2006; Landry, Wei, & Frost, 2008; Lindberg, Frost, 
Sten, & Dailard, 2006; Mested et al., 2011).  All of the studies included found that 
provider education might improve the frequency of LARC prescribing.  Two studies 
demonstrated that removal of cost as a barrier could improve the frequency of LARC 
prescribing, and two studies found that consistency in message delivery to patients from 
providers and staff could increase patient utilization of LARC.   
Recommendation for Practice Change 
The purpose of the EBPI project was to increase provider disclosure of LARC 
methods. The recommendation for practice based on the literature review was to remove 
provider barriers to prescribing LARC methods.  Because provider barriers include; lack 
of knowledge about LARC, inadequate patient teaching tools, inconsistency in LARC 
messaging among providers and staff, and issues with reimbursement for LARC 
methods, all of these were addressed in the practice change (ACOG, 2011; CDC, 2010; 
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Choice Project in Saint Louis, Missouri, was found to have developed a toolkit to address 
these concerns (Mested, et al., 2011).  The Contraceptive Choice Project demonstrated a 
significant increase in LARC utilization particularly among adolescent and young adult 
women when providers were trained in LARC eligibility, provided consistency in LARC 
message delivery, and all contraceptive methods were provided at no cost (Mested, et al., 
2011).  Contraceptive Choice Project staff members were consulted regarding 
implementing components of their project, and were forthright about limitations in 
previous stages of implementation as well as their plans for future implementation.  They 
were supportive of the utilization of their program components in the current EBPI 
project and helped guide selection of program tools to implement in the current EBPI 
project setting (See Tables 6 and 7) (H. Broughton & S. Selbert, personal 
communication, February 6, 2013).   
Toolkit Approach 
Because multiple barriers to LARC utilization were identified both in findings 
from the literature search and internally at the EBPI project site, a toolkit approach was 
selected to address many of these barriers at once.  According to Butler (2007, p. 93) “A 
toolkit is a set of materials-written documents, PowerPoint presentations, and other 
resources- that support a particular practice or program,” and can be utilized to assemble 
the best evidence on a topic into a comprehensive intervention.  The Institute for 
Healthcare Improvement (IHI) (2012) and The Agency for Healthcare Research and 
Quality (AHRQ) (2011) have suggested the use of toolkits to address multiple barriers to 
a practice change.  Both organizations have authored numerous toolkits that translate 
evidence into tools, trainings, and checklists that can be implemented in health care 
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settings.  Notably, The Contraceptive Choice Project (described above) used a toolkit 
approach to provide structured contraceptive counseling and to remove cost barriers to 
LARC (Mested, et al., 2011).  To account for these factors a subsequent PICOT question 
was created to guide the EBPI project: “Among healthcare providers in a public health 
clinic, how does utilization of an evidence-based toolkit for providers, staff, and patients 
about long acting reversible contraception (LARC), compared to no intervention, affect 
the percentage of LARC prescriptions among all contraceptive prescriptions written for 





Setting and Population 
 The EBPI project took place in an urban, publicly funded women’s health and 
family planning clinic that was part of the city health department in a medium-sized Mid-
western city.  The population of the county served by the site was just over 1 million 
people, 51.3% of whom are female.  In addition the Caucasian, African American, and 
Latino populations, there were refugee groups from Africa, the Middle East, and Asia 
(Central Ohio Hospital Council, 2013).  At the EBPI project site 37% of clients were of 
Hispanic origin and 62% of clients spoke English as their first language.  Language 
interpretation was available via telephone, video conferencing, and face to face.  The 
population of focus for the clinic was women at 100% or below of the federal poverty 
level.  Patients who were uninsured or underinsured were seen for a donation or a fee 
based on a sliding scale.  The facility averages 130 patient encounters per month (Clinic 
Site Director, personal communication March 12, 2014).      
Evidence-Based Practice Improvement Project Approval 
Agency permission was obtained from the public health clinic to conduct the 
EBPI project. Human subject’s project approval was obtained from the institutional 




Toolkit Components  
LARC methods included in the toolkit were the copper IUD (brand name 
Paragard), a progestin-containing IUD (brand name Mirena), and the progestin 
contraceptive implant (brand name Nexplanon).  A newer progestin-containing IUD 
(brand name Skyla) was not included due to inconsistent product availability and 
outcomes data at the time.  The three LARC methods included in this EBPI project had 
demonstrated increased efficacy over other contraceptive methods in a previous study 
(Kavanaugh, et. al, 2013). The increased efficacy was attributed to reduction in both user 
error and user discontinuation. Based on the success of The Contraceptive Choice Project 
several of their toolkit components were included in this EBPI project.  These included 
an initial training (a 1.5 hour PowerPoint presentation and question/answer period) for 
the clinic providers (three advanced practice nurses and one physician) as well as nurses 
(one registered nurse (RN) and 2 licensed practical nurses (LPN) and staff (administrative 
staff and medical assistants) (See Appendix E). Other toolkit components included from 
The Contraceptive Choice Project included handouts for patients in both English and 
Spanish, “scripting” to provide consistent message delivery among providers, and 
resources to ensure adequate clinic reimbursement for contraceptive prescribing (See 
Tables 6 and 7).   
Barriers and Facilitators 
An anticipated facilitator was support from the site director and the site’s medical 
director.  To maintain this support, the EBPI project leader provided clear timelines and 
reports on the EBPI project.  A second anticipated facilitator was that the clinic 
maintained on-site availability of LARC methods due to receiving Title X funding (as 
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described previously).  Another anticipated facilitator was support from one of the 
providers, a family nurse practitioner at the clinic who was motivated by her own 
Table 6   
Necessary Toolkit Components   
Product/Document Critical Components Literature Support 
 
 
Patient teaching tools 
(Method Fact Sheets) 
Address specific provider 
concerns about amount of 
time necessary to educate 
patients about insertion and 
expected side-effects. 
Literacy level 
# of printed copies and 
availability 
Available in both English 
and Spanish 
Some graphics employed 
 
 
Mested, et al. (2011) 
Provider and staff education 
(Initial training and Provider 
resource notebook/LARC 
provision guide) 
Initial provider feedback 
Time to present to providers, 
plan for follow up 
Ongoing provider feedback 




Deans & Grimes 
(2009), Kavanaugh et 
al., (2013), Lewis et 
al., (2013), Mested, et 
al. (2011), Tyler et 
al., (2012) 
Scripting to ensure consistency 
in LARC message delivery 
Understandable for all clinic 
staff 
Posted in all appropriate 
places (front desk, billing, 




Kavanaugh et al., 
(2013), Mested, et al. 
(2011) 
Billing code sheet Critical to implementation, 
currently available at 
practice 
Readily available for billing 
staff and providers 
Kavanaugh et al., 









Medical eligibility criteria for 
contraception 
 
Centers for Disease Control and 
Prevention 
Choice project Findings 
 
The Contraceptive Choice Project 
Scripted response to IUD 
commentary in the media 
 
The Contraceptive Choice Project 
Contraceptive counseling scripts 
in English and Spanish 
 
The Contraceptive Choice Project 
Contraceptive method fact 
sheets 
 
The Contraceptive Choice Project 
Contraceptive method 
frequently asked questions 
 
The Contraceptive Choice Project 
Helpful hints for LARC 
insertions and removals 
 
The Contraceptive Choice Project 
LARC insertion timing 
algorithms 
 
The Contraceptive Choice Project 
Menu of contraceptive options 
 
The Contraceptive Choice Project 
Method bridging protocol 
 
The Contraceptive Choice Project 
Signs of clinical urgency 
 
The Contraceptive Choice Project 
U.S. Selected practice 
recommendations for 
contraceptive use 2013 updates 
 
Centers for Disease Control and 
Prevention 




understanding of the current literature and her education to provide LARC methods as 
first line contraception.  This provider was educated more recently than the other two 
providers and therefore may have been more aware of recent LARC recommendations 
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and more likely to prescribe LARC methods on a more frequent basis. Table 8 shows 
EBPI project facilitators and how each was addressed during implementation. The use of 
rapid PDSA cycling was a facilitator as small tests of change offered the potential for 




Facilitators How addressed during implementation 
 
Agency buy-in (support from site director 
and medical director) Both presented the 
EBPI project at related meetings within 
the agency and invited the EBPI project 
leader to speak about the EBPI project 
whenever appropriate. 
 
Site director also looked for connections 
to other agency programs such as 
providing contraception to patient’s of the 
tuberculosis clinic. 
 
Voiced appreciation for teamwork and 






Prioritized being present at different 
agency meetings (birth outcomes, 
reducing infant mortality) to educate 
about the EBPI project 
Title X funding 
Healthy People 2020 has goal of “full 
availability” of all FDA approved 
contraceptive options at Title X funded 
sites so the agency has a broader motive 
to meet the goals of this EBPI project. 
 
Remained current and knowledgeable 
about this larger federal mandate and 
addressed it at agency meetings 
Grant in place with similar goal, which 
further motivates site director and may 
influence provider participation. 
 
Keep meticulous records for site director’s 
use 
 
 Anticipated barriers included variation in ethnicity and primary language (some 
patients did not speak English) among patients at the site (See Table 9).  To address the 
Spanish language barrier, the clinic’s two full-time Spanish interpreters were involved in 
the toolkit training.  Other languages were anticipated to remain barriers to full 
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implementation of the toolkit components.  Another anticipated barrier was the potential 
resistance of one provider at the site who expressed a bias against the follow up necessary 
after prescribing LARC methods.  In response to this provider’s initial concerns, teaching 
tools were included in the toolkit that addressed common side effects and when to call the 
clinic.  To continue to engage this provider the EBPI project leader regularly solicited her 
feedback and acted on it when appropriate.  
              Unanticipated barriers included lack of use of the toolkit by providers (other than 
participation in the initial training) and lack of provider “buy-in” about the necessity for 
change.  Another unanticipated barrier was the absence of clinical and administrative 
leadership from the site director and the medical director.  Both of these individuals had 
the opportunity to promote the EBPI project and to set goals and require adherence from 
the providers.  All three providers involved repeatedly reported that they already 
promoted LARC methods prior to the EBPI project and did not need to change any 
behaviors.  These providers’ pre-EBPI project prescribing numbers suggest that they may 
have already been promoting LARC, but still had room for improvement.  While the 
agency’s benchmarks and grant funding may have provided the site director with 
motivation to increase LARC prescribing, it was not evident that she communicated this 
to the providers. Instead, her advice to the EBPI project leader was to increase her 
physical presence at the site.  In effort to address this void in formal leadership, the 






Barriers How Barriers were addressed during 
implementation 
 
Lack of use of toolkit                                   Frequent verbal conversations about tools and 
               posted some tools in prominent locations 
 
Lack of “buy-in” about necessity               Regular modifications to plan and feedback 




Lack of formal leadership by                      EBPI project leader greater physical presence 
on site 
Site director and Medical director 
 
Language did not turn out to be a barrier because the medical director chose to 
limit LARC communication to providers and registered nurses.  Language interpretation 
was available during these encounters.  Cultural barriers were likely present, but were not 
documented in the EBPI project and were not identified as barriers by providers or staff 
in verbal discussions about the EBPI project’s progress. Interestingly, the EBPI project 
participants did not mention time, a commonly cited barrier to counseling, as a barrier 
either before or after the EBPI project implementation.  Further, cost and method 
availability, common barriers to LARC prescribing noted in the literature were not 
barriers at the EBPI project site.  
Implementation and Evaluation Plan 
Step 6 of the EBPI model is engaging in tests of change.  This is called plan, do, 
study, act, or “PDSA.”  During this phase the form developed by the Institute for 
Healthcare Improvement was used to conduct periodic evaluations of the EBPI project 
(See Appendix F).  In this process “Plan” included making a prediction about what would 
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happen and plan to test the change.  “Do” included testing the change on a small scale 
and documenting problems and unexpected observations.  Provider and staff training, and 
toolkit implementation began during the “study” phase.  The “Act” stage included 
altering the change based on the lessons learned and preparing for the next change cycle 
(Institute for Healthcare Improvement, [IHI] 2014).  This was accomplished using the 
steps outlined in Table 10.  A total of seven PDSA cycles were completed during the 12-
week EBPI project period (See Appendix G). 
Data Collection and Outcomes 
The clinic staff collected the data for the EBPI project.  The EBPI project leader 
(DNP student) was blinded to patient information.  Staff members reviewed printed logs 
of prescriptions that were organized by date and matched the contraceptive method 
prescribed with the patient’s age.  The EBPI project leader then categorized this in a 
chart.  The data were collected at the end of each of the three 4-week long periods of the 
EBPI project and the EBPI project leader shared results with each individual provider.  
After the first and second cycles of data collection, the team believed that DMPA was the 
most commonly prescribed contraceptive method.  It was only during the third data 
collection cycle when the EBPI project leader identified that DMPA was being prescribed 
at each visit (four times per year) rather than simply being prescribed once with refills.   
Numbers of DMPA prescriptions were then recalculated using DMPA prescribed during 
a visit with a provider rather than simply a DMPA prescription as criteria for being 
counted in the analysis.  Prior to this recalculation the EBPI project leader and 
participants believed that DMPA was the most commonly prescribed contraceptive 










1) LARC project site provider 
opinion survey 
 
2) Initial teachings 
 
3) Toolkit introduction 
1) Response less enthusiastic than 
anticipated 
2) Medical director stated only licensed 
personnel to be involved 
3) Clinic in-service reiterated ideas 
presented in in initial teaching 
4) No participant use of toolkit after 
initial teaching 
 





1) Continue toolkit 
implementation  
 
2) Place key algorithms from 
toolkit in prominent clinic 
locations so clinicians do not need 
to open toolkit to see algorithms. 
 
1) Clinic contact person (proposed 
champion) stated team members “had 
not had time” to look at toolkits 
(binders) or to discuss them.  
Clinicians will need additional 




1) Increase contact between EBPI 
project leader and clinic contact 
person by conducting in-person 
site visit at least weekly and email 
communication weekly 
1) Participants seem responsive to EBPI 
project leader’s presence as evidenced 
by their willingness to talk openly about 
their prescribing practices when EBPI 
project leader is present.  However, all 
participants confirmed they were not 
using toolkit at all. 
1) Clinicians will need 
additional intervention to affect 
change 
 
2) One clinician revealed she 
continues to refer to 







EBPI Project leader to review 
these. 




After checking that the content 
was the same, EBPI project leader 
posted LARC insertion algorithm 
from reproductiveaccess.org in 
provider work area with the intent 
of increasing utilization of the 
algorithm by preventing having to 
look it up when needed. 
 
Identified that LPNs and RNs were 
administering DMPA injections (which 
are administered every 12-15 weeks) 
and therefore presented an opportunity 
to counsel patients about LARC times 
per year 
Plan additional training for 
LPNs and RNs to counsel about 
LARC at DMPA injection visits. 
Received approval from medical 




Plan to educate LPNs and RNs 
about how to counsel about 
LARC so they could do so at 
DMPA injection visits 
Only one individual available on day of 
planned training. 
This nurse was enthusiastic about 
counseling. 
Plan to train additional LPNs 
and RNs in future weeks.  
 
Compile data from first 4 weeks 





Share results (results %) and 
observations from first 4 weeks of 
EBPI project implementation and 
illicit feedback from participants 
on why they think changes were 
made 
Hoped this conversation would 
encourage provider buy-in for the 




Clinicians reported that they saw 
minimal change in counseling and 
prescribing habits because they believed 
they were already counseling and 
prescribing effectively. One clinician 
did indicate that she had begun 












1) Planned to compile data from 
second 4 weeks of EBPI project to 
see if positive prescribing trend 
persisted and present to 
participants 
During data compilation EBPI project 
leader realized that clinicians were 
generating a new DMPA prescription 
with every injection rather than 
generating one prescription yearly with 
refills.  This realization led to a 
significant re-examining of EBPI 
project outcomes. 
At the same time the clinic received 
budget cuts that disrupted data 
collection and limited participant 
availability to meet with EBPI project 
director. 
 
In the last week of the EBPI 
project overall project findings 
were shared with each 
participant and the LARC 
project site provider opinion 
survey was distributed in order 
to compare responses with those 
collected prior to the EBPI 
project 
 






Quantitative outcomes were evaluated by tracking the number and type of 
prescriptions written over the three-month EBPI project period.  The plan prior to 
implementation was to collect information about how the toolkit components were used 
through a written “parking lot” (a notebook in the clinic’s break room where providers 
and staff could comment anonymously on the progress of the EBPI project) and 
conversations with clinic providers and staff.  Unexpectedly, the “parking lot” was never 
utilized and repeated conversations and alterations to the PDSA cycles still resulted in no 
use of the written materials in the toolkit by the providers or staff.  Qualitative outcomes 
were collected through conversations between the EBPI project leader and the clinic 
providers and staff as well as through the LARC project site provider opinion survey that 
was administered both before and after the EBPI project implementation.   
There were seven PDSA cycles during the 12-week study period.  Cycles were 
intended to occur weekly, but unforeseen events such as personnel availability made this 
impossible.  In the first cycle the LARC project site provider opinion survey was 
administered by providing the survey questions on paper to clinic providers.  The surveys 
were returned to a pile anonymously.  The initial teaching was conducted (described 
above) and the written toolkit (a collection of documents organized in a three ring binder 
and distributed to each individual provider and work area) was introduced to the 
participants.  Responses were less enthusiastic than anticipated.  After the initial teaching 
very few questions were asked.  When the EBPI project leader asked what components of 
the toolkit attendees could picture themselves using one provider said “I just need time to 
digest this,” and no one else responded.  Another unanticipated barrier was that the 
medical director stated after the initial teaching that he wanted the scripting portion of the 
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toolkit limited to providers and nurses due to “medico-legal concerns.”  A significant part 
of the toolkit concept was to have consistency in message delivery from all individuals 
that patients at the site might interact with.  The EBPI project leader reiterated that the 
goal was for no individual’s bias to create a barrier to the patient’s method choice. 
Further, a required staff in-service for the entire facility, that the clinic is a part of, 
included a presentation on adolescent health that reiterated the same themes presented in 
the initial teaching.  While this was positive in terms of reinforcing concepts, it also took 
away the day that EBPI project participants had anticipated being able to review the 
toolkit.  The clinic liaison reported that no one had opened the binders during the first 
week.   The EBPI project leader’s initial reaction was that participants might have been 
given too many resources at once.  For cycle two the EBPI project leader and site director 
decided to post keys (from the toolkit) in prominent locations around the clinic where 
attendees would see them without having to open the toolkit (See Appendix H).  
Specifically, algorithms were placed on the walls in provider offices and on the 
medication sample closet (where providers would go to retrieve contraceptive methods).  
At the end of cycle two participants reported that they still had not even opened the 
binders.  The EBPI project leader and the site director decided to try more “face time” 
between the EBPI project leader and EBPI project participants as the next intervention.  
This was based on the site director’s expert opinion having worked in a leadership role 
with this particular group of clinicians. 
 For cycle three the EBPI project leader planned to visit the clinic at least once per 
week and, in addition, to exchange email with the project liaison once per week.  The site 
director had identified an EBPI project liaison prior to beginning the EBPI project.  This 
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individual was chosen due to her interest in promoting change at the site as perceived by 
the site director.  During these visits and emails the EBPI project leader inquired about 
the participants’ prescribing patterns and their use of the toolkits.  Participants became 
more talkative with the more frequent in-person visits during this cycle, but still not one 
participant opened or utilized the written materials.  An unexpected finding during this 
cycle was that one clinician revealed she was consulting an algorithm for LARC insertion 
from another source when she had questions about when to start a method.  This clinician 
stated she was more comfortable with this algorithm (compared to the ones in the toolkit 
that were now also posted around the clinic) because she had already been using it and 
that she looked it up online each time she wanted to access the LARC insertion 
algorithm.   
 In response to the clinician who was using an algorithm from an outside source, 
for the fourth cycle the algorithm in question was examined for accuracy and found to be 
nearly identical to the algorithm in the implemented toolkit.  Therefore, the EBPI project 
leader printed copies of this algorithm and posted them alongside the toolkit algorithms 
in the provider offices and on the door of the sample prescription closet.  In person 
conversations with participants during cycle four revealed that when patients presented 
for DMPA injections (every 11-13 weeks) they were seen by a licensed practical nurse 
(LPN) or registered nurse (RN) rather than a provider and therefore, if contraceptive 
counseling was going to occur at these visits the LPNs and RNs would need additional 
training in LARC counseling.  Permission to provide this training was obtained from the 
clinic’s medical director.  
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 For cycle five, additional training for LPNs and RNs in how to counsel about 
LARCs was planned.  This included information about determining appropriateness of 
LARC methods for individual patients and scripting (from the toolkit) about the benefits 
of LARC methods.  Unfortunately, due to illness, only one nurse was available for 
training during the planned time.  This individual was very responsive to the discussion 
of counseling about LARCs at DMPA injection visits and it was revealed that this 
individual was not previously aware that a LARC method could be initiated before the 
subsequent DMPA injection was due.  Conversations with participants continued to 
reveal that no participant had read or utilized any written component of the toolkit-
including the posted algorithms. 
 For the sixth cycle, data from the first four weeks of the EBPI were compiled and 
evaluated.  LARC prescribing for women ages 15-25 had increased from 6% to 18%. 
Since findings were positive despite lack of use of the written components of the toolkit, 
the EBPI project leader met with each participant individually to illicit feedback from 
participants on why they thought prescribing changes had occurred.  Clinicians responded 
that they saw minimal change in counseling and prescribing habits because they believed 
they were already counseling and prescribing effectively.  One clinician did indicate that 
she had begun counseling about LARC methods first.  Again, each participant verified in 
conversation with the EBPI project leader that she had not utilized the written toolkit 
materials in any way and did not foresee him or herself doing so in the future.  Other 
providers responded verbally and by email that they did not know why a change was 
noted, that they did not do anything to affect the change, and that it may have been due to 
chance.  Specific responses included the following: “I’m not sure why there has been a 
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difference,”  “Maybe everyone feels more comfortable discussing LARCs with our 
patients since we received the education from you?  Or maybe it’s a coincidence,”  “It’s 
hard to say, but it’s a good thing!” and “I think the only thing that has changed with my 
practice is that when I list contraceptive options, I start with the LARCs and work my 
way down.  I used to start with the pills because that’s what most patients are most 
familiar with.”  
 For cycle seven the plan was to compile and evaluate data from the second four 
weeks of the EBPI project.  During data compilation the EBPI project leader realized that 
clinicians were generating a new DMPA prescription with every injection rather than 
generating one prescription yearly with refills.  Because data was being counted based on 
the number of prescriptions generated for each method type, this was essentially 
quadrupling the number of prescriptions for DMPA.  The EBPI project leader and the 
data collector reexamined the numbers, altering the criteria to reflect prescriptions 
generated during a visit with a clinician only.  At this point overall data for the entire 
EBPI project period was shared with each participant.  At the end of cycle seven 
participants were once again congratulated for the positive change in prescribing for 
women aged 15-25 and were asked to complete the LARC project site provider opinion 
survey (identical to the one given before the initial teaching), again, on paper and 
returned anonymously, in order to evaluate any changes in opinion about LARC methods.  
Evaluation and Outcomes 
 The EBPI project leader identified several components to evaluate during the 
EBPI project period.  Initially, the number of LARC prescriptions as a percentage of 
overall contraceptive prescriptions was recorded.  This was done using the clinic’s 
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electronic health record and was tallied by a staff nurse. The EBPI project leader 
measured the frequency with which toolkit components were used by conducting 
frequent informal conversations with and participants.  Participant opinions were 
measured by administering the same survey before and after the intervention (see Table 
11).   
Table 11 
 
Evaluation and Outcomes 
Evaluation component Measurement approach and outcome 
 
Number of LARC prescriptions written as 
a percentage of overall contraceptive 
prescriptions written during the study 
period 
*Electronic health record allowed for 
tracking this measure. Nurse on clinic staff 
tabulated prescriptions by prescription 
type, month, and patient’s age.  
 
Frequency with which toolkit components 
were used 
*Toolkit components were not used, other 
than possibly algorithms that were posted. 
Changes in provider counseling process 
were determined through conversations 
with individual participants. 
 
How patient materials were utilized Materials provided in toolkit were not 
utilized 
 
Participant opinion Opinion surveys administered before and 
after the intervention revealed few changes. 
Most notably, one provider began 
counseling about LARC methods at the 
beginning of her contraceptive counseling 





IV.   FINDINGS 
Population Demographics 
During the study period 42 women ages 15-25 received contraceptive 
prescriptions as did 64 women ages 26 years and older for a total of 106 women.  The site 
primarily served women with incomes at or below 100% of the federal poverty level.  
Data about language is not available for the study period, but in the most recent year that 
data was collected at the site, 38% of women did not speak English as their primary 
language or did not speak English at all (Clinic Site Director, personal communication 
March 12, 2014).      
Outcomes of the Evidence-Based Practice Improvement Project 
  Outcomes were tracked using the data collection tool (See Table 12).  Prescribing 
of LARC methods for women ages 15-25 increased over the course of the EBPI project 
period from 6% to 20% of all contraceptive prescriptions written for this age group (See 
Table 13).  However, LARC prescribing in women 26 and older declined during the 
EBPI project period from 30% to 18%.  Prescribing outcomes were tracked by method 
type (progestin IUD, copper IUD, contraceptive implant, DMPA, or contraceptive pills), 
whether the method was a LARC or not (see Table 13), and by age group (15-25 years, or 
26 years and older) (see Table 14). Clinic providers and staff did not utilize the toolkit as 
expected.  It is possible that interaction with the EBPI project leader was the only factor 
in altering prescribing patterns.  No one wrote in the parking lot.  All clinicians stated 





Data Collection Tool 
 Oct. 1-Oct. 31 
2013 
 
April 21-May 18 
2014 
May 19-June 15 
2014 
June 16-July 13 
2014 
Number of prescriptions for contraceptive Implant in 
women 15-25 
 
1 2 2 1 
Number of prescriptions for contraceptive Implant in 
women 26 and older 
 
3 1   
Number of prescriptions for Progestin-containing IUS 
in women 15-25 
 
 1 1 1 
Number of prescriptions for Progestin-containing IUS 
in women 26 and older 
 
3 2 2 1 
Number of prescriptions for copper IUD in women 15-
25 
 
    
Number of prescriptions for copper IUD in women 26 
and older 
 
3   1 
Number of prescriptions for DMPA in women 15-25 
 
4 5 6 5 
Number of prescriptions for DMPA in women 26 and 
older 
 
4 3 8 7 



















Percentages of all Contraceptive Prescriptions that are LARC Methods by Patient Age 
 Oct. 1-Oct. 31 2013 
 
April 21-May 18 
2014 
May 19-June 15 
2014 
June 16-July 13 
2014 
 
Percent of all contraceptive prescriptions that are 
LARC methods in women 15-25 
 
1/16=6% 3/17=18% 3/15=20% 2/10=20% 
Percent of all contraceptive prescriptions that are 
LARC methods in women 26 and older 
 
9/27=30% 3/17=18% 2/25=8% 2/22=9% 
Percent of all contraceptive prescriptions that are 
LARC methods in all women 




Number of Prescriptions by LARC vs. Other Methods by Patient Age 
 Oct. 1-Oct. 31 2013 
 
April 21-May 18 
2014 
 
May 19-June 15 
2014 
June 16-July 13 
2014 
Number of prescriptions for other contraceptive 
methods in women 15-25 
 
15 14 12 8 
Number of prescriptions for other contraceptive 
methods in women 26 and older 
 
18 14 23 20 
Number of prescriptions for LARC methods in 
women 15-25 
 
1 3 3 2 
Number of prescriptions for LARC methods in 
women 26 and older 






counseling had not changed.  One exception to this was that one provider noted she had 
begun counseling about LARC methods at the beginning of a contraceptive discussion 
rather than at the end.  The EBPI leader learned that at this site nurses attend ¾ of all 
DMPA visits and that the initial understanding among the team about DMPA trends in 
usage was inaccurate.  There were no observations made about cultural variations in 
LARC desire among patients.  
 Changes in provider opinion and attitude were measured qualitatively through 
administration of the same LARC project site provider opinion survey before and after 
the intervention (See Appendix A).  Items that remained consistent both before and after 
the EBPI project were: Concern about difficult device insertions and removals and 
concern about patient complaints of unpredictable bleeding.  Changes noted in the LARC 
project site provider opinion survey that followed the intervention included: One provider 
shifting from counseling about LARC in patients not wanting pregnancy for 1.5 years to 
patients not wanting pregnancy for one year and one provider counseling about LARC at 
the beginning of contraceptive counseling rather than at the end. 
The question was “Among healthcare providers in a public health clinic, how 
does utilization of an evidence-based toolkit for providers, staff, and patients about long 
acting reversible contraception (LARC), compared to no intervention, affect the 
percentage of LARC prescriptions among all contraceptive prescriptions written for 
women ages 15-25 over three months.”  The goal of the EBPI project was to increase the 
percentage of contraceptive prescriptions that were LARC methods written for patients 
aged 15-25.  The goal was met with regard to these patients. LARC prescribing increased 
from 6% to 20% for patients in this age group.  Because the numbers of patients in this 
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age group was small at the EBPI project site, the EBPI project was expanded to address 
contraceptive prescribing for women aged 26 and older.  The goal was not met with 
patients aged 26 and older (See figures 4 and 5). 
 
Figure 4. July 2014 Contraceptive Prescriptions at EBPI project site for patients age 15-




Figure 5. July 2014 Contraceptive Prescriptions at EBPI project site for patients of all 
ages.  LARC-long acting reversible contraceptive 
Method Type Ages 15-25
LARC 20%
Other 80%





Economic outcomes  
During the EBPI project period an additional two or three women aged 15-25 
years received contraceptive methods that decreased their risk of pregnancy over the 
ensuing year from 8% to less than 1%.  If only one woman avoids an unintended 
pregnancy due to this intervention a cost savings could be realized.  According the 
Guttmacher Institute (2011), unintended pregnancy costs U.S. taxpayers approximately 
eleven billion dollars per year.  If 60% of young women using contraception used the 
most effective methods, as they did in The Contraceptive Choice Project, significant cost 
savings could be realized.  Laliberte and colleagues (2014) reiterated that provision of 
any method of contraception, but especially LARC, is associated with significant cost 
savings when compared to the cost of unintended pregnancy.  
Findings from opinion surveys 
The first question in the LARC project site provider opinion survey was “What 
methods come to mind when you think of ‘long acting reversible contraceptives’ 
(sometimes called LARC methods)?”  Prior to EBPI project implementation providers 
listed correct responses but responses included a variety of brand names and varied 
vocabulary about method type.  After the EBPI project, answers to this question included 
more streamlined terminology.  Providers answered with only two terms “IUDs” and 
“Nexplanon.” 
The second question was “What are your initial thoughts when you hear the term 
long acting reversible contraceptives?”  Before the EBPI project implementation 
providers mentioned efficacy and side effects in response to their initial thoughts 
regarding LARC methods.  After the EBPI project, one participant was better able to 
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quantify the efficacy by stating that LARC methods are as effective as tubal ligation.  
Both before and after the EBPI project it was mentioned that the term “LARC” is not 
patient friendly.  Of note, after the EBPI project, one participant responded to this 
question with the concern that LARC methods can be “tricky to insert/remove.” 
The third question was “Are there certain patients for whom you are more or less 
likely to discuss long acting reversible methods?”  This group of providers did not 
express preference either before or after the EBPI project about which women were 
appropriate candidates for LARC in terms of age or number of previous pregnancies.  
Notably, prior to the EBPI project one respondent stated that she/he would not consider 
LARC for a patient who wanted to avoid pregnancy for less than 1.5 years.  After the 
EBPI project there was also only one response regarding length of time the patient 
desired to avoid pregnancy and that time it was one year.  
The fourth question was “What are barriers to using these methods for you as a 
practitioner?”  Both before and after the EBPI project themes that emerged in response to 
this question included patient misinformation as well as participant advantage to having 
all of the LARC methods available on site.  Prior to the EBPI project respondents 
expressed concern about having had “several” difficult insertions and removals, the 
bleeding profile with Nexplanon, cost, and the “invasiveness” of the methods.  After the 
EBPI project concerns included perceived patient lack of follow through with follow-up 
visits and the mention of the “occasional” difficult insertion. 
The fifth question was “What are some barriers in your practice for patients to 
receive these methods?”  Before the EBPI project answers included cost, personal bias, 
appointment times, and patient fear of insertion or patient fear due to misinformation in 
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the media.  After the EBPI project one respondent exclaimed “very few!” while others 
mentioned lack of back up for difficult insertions and insertion failure.  
The sixth and final question was “What do you perceive as patient barriers to 
use?”  Prior to the EBPI project respondents mentioned stock (meaning having the 
method(s) available on-site), patients needing multiple visits if pregnancy status could not 
be determined, fear of pain, bleeding pattern, cost, and patient concern that the methods 
were “too permanent.”  After the EBPI project, responses to this question included the 
invasiveness of the procedure, bleeding pattern, misperceptions about risks, and the 
methods being “too long-term.” 
Overall persistent themes included bleeding pattern, difficult insertions, and 
patient misconceptions about risk and permanency of LARC methods.  Changes noted 
included a better understanding of LARC methods efficacy, consistency of language 
among respondents about which methods are LARC methods.  After the EBPI project no 
respondents mentioned cost, appointment times, or method availability as barriers 
possibly indicating their increased awareness that these barriers were not applicable at 
their site.  
Participants repeatedly reported that they never opened the toolkit.  Interestingly 
they did not read the section on difficult insertions though this continued to be a concern 
for them throughout the EBPI project.  Additionally, it is challenging to measure how 
frequently participants looked at the posted algorithms or how their prescribing habits 
may have changed based on conversations with the EBPI project leader.  Findings are 
extrapolated from what participants told the EBPI project leader and the changes noted in 
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the LARC project site provider opinion surveys administered before and after the EBPI 





Responses to LARC Project Site Provider Opinion Survey  
Question Responses before EBPI project 
implementation 
Responses after EBPI project 
implementation 
 
What methods come to mind when you think 
of “long acting reversible contraceptives” 
(sometimes called LARC methods)? 
 
Nexplanon, Mirena, Paragard, Skyla,  
 
Nexplanon, IUDs,  
 
IUD, implants, injectables,  
IUDs and nexplanon,  
 
Nexplanon, IUDs (both) 
 
What are your initial thoughts when you hear 




Excellent methods for contraception.  
Sometimes less desirable side effects 
 
Efficacy, convenience, cost not a 
patient/client friendly term 
 
Efficacy and ease of use 
Not a patient friendly phrase 
Reliable, safe, can be tricky to 
insert/remove 
As effective as a tubal ligation 
 
Are there certain patients for whom you are 
more or less likely to discuss long acting 
reversible methods? 
 
More likely: pregnant patients, 
teenagers, less likely: patients who 
come in requesting shorter-acting 
methods 
 
More likely: women who will use 




Discuss with everyone 
 
Not really-maybe if their personal 
situation didn’t seem appropriate for 
LARC, I guess. 
 
Almost everyone, not someone who 
wants a pregnancy in 1 year 
 







Question Responses before EBPI 
implementation 
Responses after EBPI project 
implementation 
 
What are barriers to using these methods for 
you as a practitioner? 
 
Nexplanon’s bleeding profile makes me 
wary, recently had several difficult IUD 
removals which also makes me wary 
 





We are very fortunate to have all 
methods available including for women 
without insurance 
 
Misinformation that patients receive 
from media, friends, etc.  
Lack of patient follow-through 
(sometimes patients don’t return for 
visits) 
 
We’re fortunate to have methods 
available for uninsured  
 
Occasionally have difficulty with 
insertion of IUD 
 
I can’t think of any 
 
What are some barriers in your practice for 
patients to receive these methods? 
 
Scary, commercials about Mirena, cost, 
hearing negative stories from family 




Cost, personal bias 
 
Limited appointment times (sometimes) 
 
Very few! We have LARCs available 
any time and are, as a team, very pro-
LARCs.  
 
Maybe that we don’t have a lot of back 
up for difficult insertions 
 
Not many-usually if they opt to not use 
 
I am happy to insert any LARC, but 
sometimes IUD insertion fails for 
whatever reason, so after that failure 








Question Responses before EBPI 
implementation 
Responses after EBPI project 
implementation 
 
What do you perceive as patient barriers to 
use? 
 
Sometimes run out of Nexplanon, don’t 
stock Skyla, patients come in with 
recent unprotected sex and have to 
return in 2 weeks for insertion 
 
Fear of painful insertion, some think it 
is “too permanent” even if they don’t 
want pregnancy for several years, 
partner dissatisfaction, s/e (bleeding) 
 
Education, cost, lack of support 
 
Fear, misinformation, negative “word 
of mouth” info, cultural bias 
 
Having something “inserted” makes 
patients nervous. Also, the varied 
bleeding pattern of the Nexplanon turns 
some patients off. 
 





Fear/worry about side effects 
 
Seems “too long-term,” They don’t live 
in a long-term world often 
 
Mostly, the barriers to getting care at all 







V.  DISCUSSION 
Based on the results of the internal and external information gathered prior to the 
EBPI project, the EBPI project leader believed that giving providers the tools to respond 
to their concerns about LARC prescribing would result in an increase in LARC 
prescriptions as a percentage of all contraceptive prescriptions.  The EBPI project leader 
also assumed that providers agreed that change was necessary and were motivated to 
change their practice. The contribution to knowledge that stems from this EBPI project is 
that, in addition to tools, resources, and leadership support, provider buy-in is necessary 
for change to take place.  
 The purpose of the EBPI project was to increase provider disclosure of LARC 
methods and the goal was to increase the percent of contraceptive prescriptions that were 
LARC methods for women ages 15-25 years.  In the original Contraceptive Choice 
Project investigators found that 60% of adolescent women chose LARC methods when 
cost, availability, and misinformation were removed as barriers (Mested, et al., 2011).  In 
this EBPI project, LARC prescribing increased from 6% to 20% of all contraceptive 
prescriptions for women aged 15-25.  Notably, the actual numbers of patients mean that 
results are unlikely to have reached statistical significance and could have been due to 
chance or to other variables.  In The Contraceptive Choice Project, trained contraceptive 
counselors used scripted materials to counsel about LARC and other methods and 
reported the patient’s chosen method to the physician or nurse practitioner.  In this EBPI 
project, the same scripting was made available to the healthcare providers, but they 
 
 56 
elected not to use it.  In The Choice Project, all staff was trained in LARC messaging to 
ensure message consistency to patients.  In this EBPI project all staff was present for the 
initial training, but unlicensed personnel where prohibited from communicating with 
patients about the patient’s choice of contraceptive method.  Notably, in this EBPI 
project, there was not always a clinician on-site who could assist with challenging LARC 
insertions.  It is possible to infer that because The Contraceptive Choice Project was a 
research project, all clinicians in that project had “buy-in” and felt competent performing 
LARC insertions. Therefore fear of insertion difficulty or failure likely played less of a 
part in clinician decision making in that project.  In both The Choice Project and this 
EBPI project, all methods of contraception were available the day of the initial visit as 
cost was not a barrier. Limitations in this EBPI project included the small sample size and 
the limited time frame of the intervention.   
Dissemination of Findings 
Step 7 of the EBPI model is “Disseminate best practices.”  The EBPI project 
leader and site director plan to present findings from the project at the annual project fair 
at the Ohio Nurses Association and at the annual state of Ohio gathering of Certified 
Nurse Midwives.  Further, findings from the EBPI project may be implemented in other 
clinics run by the same public health facility as well as other local clinics receiving Title 
X funding.  Finally, the EBPI project leader plans to present findings to her APRN 
students in order to affect change at their practice sites.  Stakeholders included patients 
and their families, the clinic staff and providers, and the public health organization that 
includes the clinic.  Stakeholders in dissemination include any clinicians who can learn 
from the project and their future patients.  Individuals directly involved in the EBPI 
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project, in addition to the EBPI project leader, included the clinic director, the three 
advanced practice nurses at the site, the medical director, and the clinic staff.  
Future Recommendations & Conclusion 
 Because the problem of unintended pregnancy persists and major professional 
organizations support increased LARC prescribing as one method of addressing the 
problem, this project cannot be abandoned.  Recommendations for the future include 
surveying providers prior to implementation of any project to assess whether providers 
perceive that change is necessary.  Second, a recommendation for the future is for 
leadership to clearly communicate a goal and a strategy for reaching that goal when a 
change is desired.  In this EBPI project providers were given tools and resources but not 
required to use them.  Finally, it might be helpful to utilize a change theory in addition to 
the EBPI model in order to identify and address barriers to change present that may 
prevent full implementation of the project. 
Strength in the implementation of this EBPI project was the use of the PDSA 
model.  When it was discovered that the written portion of the toolkit was not being used, 
it was important to identify an intervention that might be more effective.  A thought for 
the future would be to verbally address each concern with participants as it arose.  For 
example, the EBPI project leader could provide training on what to do to make IUD 
insertions less difficult or could review charts to identify missed opportunities for use of 
the toolkit components.  Participants may be more responsive to practical application of 
components of the tool kit rather than access to a written description of a protocol.  
However, if they do not buy-in to the idea that change is necessary it is unclear that any 
intervention would work. 
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  An additional limitation of the EBPI project was that site leadership did not set 
expectations for follow through on use of the toolkit components.  The ideal next step 
would be to continue the EBPI project at the same site with modifications to assess 
provider buy-in and leadership requirement of available tools and resources.  Another 
possible addition would be to trigger providers with a pop up message in the electronic 
health record recommending LARC whenever a contraceptive prescription was ordered.  
Summary  
According to Guttmacher Institute (2013) American women spend an average of 
30 years avoiding pregnancy.  Increasing provider disclosure of LARC methods is 
critical, as LARC methods have been shown to reduce the rates of user error and 
unintended pregnancy, particularly among adolescent and young women.  Therefore, it is 
the ethical duty of all providers who care for women to educate their patients about the 
full range of contraceptive options and to work toward full availability of these options 
for women of all ages and socioeconomic groups.  When healthcare facilities that serve 
low-income women fail to provide access to and advocacy for LARC, this population 
remains unnecessarily vulnerable to unintended pregnancy.  Additional pregnancies and 
children place a disproportionate burden on impoverished women, further limiting their 
access to education and employment and often keeping them in unhealthy relationships 
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Patient and Provider Surveys 
PATIENT SURVEY 
 
1) What kinds of birth control are you aware of? 
 
2) What type of birth control would you recommend to a friend? 
 
3) What myths or rumors have you heard about certain types of birth control? 
 
4) If you could have any kind of birth control you wanted for free, what would you 
want? 
 
5) If your doctor (or other healthcare provider) recommended a long-term form of 







What methods come to mind when you think of “long acting reversible contraceptives” 
(sometimes called LARC methods)? 
 
 
1) What are your initial thoughts when you hear the term long acting reversible 
contraceptives 
 
2) Are there certain patients for whom you are more or less likely to discuss long 
acting reversible methods? 
 
3) What are barriers to using these methods for you as a practitioner? 
 
4) What are some barriers in your practice for patients to receive these methods? 
 





Patient Survey Results from COHMAB project 
And 
Provider Survey Results from COHMAB project 
LARC COHMAB PATIENT SURVEY 
 













Talk to your doctor 2 
 
8) What myths or rumors have you heard about certain types of birth control? 
 
IUDs 
“Could still get pregnant and it could hurt the baby” 
Cause infection 
Change period 
“IUDs fall out and hurt” 
hair falls out 
Negative Mirena adds on TV 
 
Other 
Cancer from pills 
Not 100% effective 
Bruising from Nexplanon 
Sex feels better without birth control 
Pills make you gain weight 
 
9) If you could have any kind of birth control you wanted for free, what would you want? 
Condoms 2 
Mirena 1 
1 additional respondent said “something like an IUD, but one that doesn’t hurt” 
 
10) If your doctor (or other healthcare provider) recommended a long-term form of birth 





“Don’t like things in my body” 
“Would think about it, but only after having children” 




Provider Survey Results from COHMAB project 
 
LARC COHMAB PROVIDER SURVEY 
5 Respondents 
 
1) What methods come to mind when you think of “long acting reversible contraceptives” 






2) What are your initial thoughts when you hear the term long acting reversible 
contraceptives 
 
Good choice for many clients 
Multiple options, good methods typically 
Wise & Responsible Decision 
Wonderful I know a lot of women who would benefit from this form of contraceptive; 
however, cost could be a factor 
More patients should use them 
 
3) Are there certain patients for whom you are more or less likely to discuss long acting 
reversible methods? 
 
I discuss a reproductive plan with all clients 
 
IUD/Paragard: - less likely- patients with no children whom want children in the future -
more likely older patients 40+ whom are high risk in regards to OB, to prevent 
pregnancy, women whom are done having children but not 100% sure Implant more 




NO, however woman without insurance may not be able to afford these methods 
 
Ones who seem very intolerant of bleeding 
 








Our Clinic is a Prenatal Clinic only. We do not give birth control but we can discuss 
options and provide them with community resources to receive the birth control of 
choice. 
 









none- several physician do these procedures 
 
False information from parents and grandparents. Patients may also experience Insurance 
problems. 
 
Cost Site of mobile, cannot provide direct services, however, can refer to our hospital site 
clinics. 
 
patients not having insurance, but being outside the parameters of LARC eligibility 
 
6) What do you perceive as patient barriers to use? 
 
Concerns about side affects 
 
side effects, risk for perforation (IUD/Paragard), irregular periods, what they hear from 
friends and family 
 
Not being responsible and false information received from family members. 
 
Cost Fear of not getting pregnant again 
 
Bleeding and cramping that they will experience. Even when you educate, they call and 


















1. Who	were	the	guideline	developers?	 	 	 	 	 ________________________	
2. Were	the	developers	representative	of	key	stakeholders	
in	this	specialty	(interdisciplinary)?	 	 	 	 	 Yes	 No	 Unknown	
	
3. Who	funded	the	guideline	development?	 	 	 	 _______________________	
4. Were	any	of	the	guideline	developers	funded	researchers	
of	the	reviewed	studies		 	 	 	 	 	 Yes	 No	 Unknown	
5. Did	the	team	have	a	valid	development	strategy?	 	 	 Yes	 No		 Unknown	
6. Was	an	explicit	(how	decisions	were	made),	sensible	and	
impartial	process	used	to	identify,	select	and	combine	
evidence?	 	 	 	 	 	 	 	 Yes	 No	 Unknown	
7. Did	its	developers	carry	out	a	comprehensive,	reproducible	
literature	review	within	the	past	12	months	of	its	publication/	
revision?	 	 	 	 	 	 	 	 Yes	 No	 Unknown	
8. Were	all	important	options	and	outcomes	considered?	 	 	 Yes	 No	 Unknown	
9. Is	each	recommendation	in	the	guideline	tagged	by	the	level/	
strength	of	evidence	upon	which	it	is	based	and	linked	
with	the	scientific	evidence?	 	 	 	 	 	 Yes	 No	 Unknown	
10. Do	the	guidelines	make	explicit	recommendations	(reflecting	
value	judgments	about	outcomes)?	 	 	 	 	 Yes	 No	 Unknown	
	
11. Has	the	guideline	been	subjected	to	peer	review	and	testing?	 	 Yes	 No	 Unknown	
	
APPLICABILITY/GENERALIZABILITY	
12. Is	the	intent	of	use	provided	(e.g.	national,	regional,	local)?	 	 Yes	 No	 Unknown	
13. Are	the	recommendations	clinically	relevant?	 	 	 	 Yes	 No	 Unknown	
14. Will	the	recommendations	help	me	in	caring	for	my	patients?	 	 Yes	 No	 Unknown	
15. Are	the	recommendations	practical/feasible	
(e.g.	resources	[people	and	equipment]	available?	 	 	 Yes	 No	 Unknown	
16. Are	the	recommendations	a	major	variation	from	current	practice?	 Yes	 No	 Unknown	






























































Recall the rate of unintended pregnancy nationally 
State the most effective forms of contraception 
State factors that have been demonstrated to increase LARC method disclosure by 
providers 
State resources for LARC prescribing questions including The Choice Project algorithms 




 Clinical Issues 
 1) Unintended pregnancy 
 2) LARC utilization 
 The Problem 
 Half of all pregnancies in the U.S. are unintended (of these almost half are due to 
incorrect contraceptive use) 
 82% of teen pregnancies are unintended 
 LARC Methods 
 Contraceptive Methods 
 Current Contraceptive Use 
 The Problem 
Long-Acting Reversible Contraceptives (LARC) including IUDs and the contraceptive 
implant are much more effective than pills at preventing unintended pregnancy but are 
underutilized. 
 Benchmarks 
 Healthy People 2020 advocates for all title X funded clinics providing the full 
range of FDA approved contraceptives 
 Barriers to increasing LARC use 
 Current literature demonstrates that clinician misunderstanding can be a barrier to 
full LARC prescribing 
 Literature Continued 
 Patients-  
Look to providers for contraceptive advice 
 Providers- 





 Teens who heard of IUDs from a healthcare provider were almost 3x as likely to 
be interested in using them 
 Conclusion 
Provider education is important to increasing LARC utilization 
 CDC guidelines (endorsed by ACOG) 
 Features of a LARC friendly practice 
 All women, including teens, are presumed to be good LARC candidates until a 
medical history indicates otherwise.  
 Staff are trained to accurately respond to common LARC patient questions and 
concerns to encourage continuation and satisfaction.  
 LARC is always discussed as the first-line option for all women, including teens. 
 What are we doing at CPH? 
 CPH LARC utilization 
 Organizational goals 
 Facilitators 
 The Next Step… 
One project was identified in the literature that has an existing set of interventions to 
increase LARC prescribing.  
The Contraceptive Choice Project includes: 
*Provider and staff training tools to address barriers to disclosure 
*Scripted patient education to improve consistency in message delivery 
 The Next Step… 
 American College of OB/GYN (ACOG) has existing billing and coding tool 
 CDC has existing medical eligibility criteria tool 
 Choice Project LARC Insertion Algorithm 
 Intervention and Evaluation 
 Intervention: LARCkit (provider resource notebook) 
 Goal: Increase the percentage of contraceptive prescriptions that are LARC 
methods 
 Weekly Evaluations  
 So What? 
 When healthcare facilities that serve low-income adolescent and young adult 
women fail to provide full disclosure of LARC methods, this population remains 
unnecessarily vulnerable to unintended pregnancy 
 What do you know about cost? 









Institute for Healthcare Improvement PDSA Tool 
 
Science of Improvement: Testing Changes 
Once a team has set an aim, established its membership, and developed measures to determine 
whether a change leads to an improvement, the next step is to test a change in the real work 
setting. The Plan-Do-Study-Act (PDSA) cycle is shorthand for testing a change — by planning it, 
trying it, observing the results, and acting on what is learned. This is the scientific method, used 
for action-oriented learning. 
  See also: Tips for Testing Changes, Linking Tests of Change, Testing Multiple Changes, 
Implementing Changes, Spreading Changes. 
Reasons to Test Changes 
   To increase your belief that the change will result in improvement. 
   To decide which of several proposed changes will lead to the desired 
improvement. 
   To evaluate how much improvement can be expected from the change. 
   To decide whether the proposed change will work in the actual 
environment of interest. 
   To decide which combinations of changes will have the desired effects on 
the important measures of quality. 
   To evaluate costs, social impact, and side effects from a proposed change. 
   To minimize resistance upon implementation. 
Steps in the PDSA Cycle 
Step 1: Plan 
Plan the test or observation, including a plan for collecting data. 
   State the objective of the test. 
   Make predictions about what will happen and why. 
   Develop a plan to test the change. (Who? What? When? Where? What 
data need to be collected?)   
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 Step 2: Do 
Try out the test on a small scale. 
   Carry out the test. 
   Document problems and unexpected observations. 
   Begin analysis of the data. 
Step 3: Study 
Set aside time to analyze the data and study the results. 
   Complete the analysis of the data. 
   Compare the data to your predictions. 
   Summarize and reflect on what was learned.   
  Step 4: Act 
Refine the change, based on what was learned from the test. 
   Determine what modifications should be made. 
   Prepare a plan for the next test. 












PDSA Cycles 1-7 
 
PDSA WORKSHEET 
Cycle: 1 Date of test: 4/21/14-
4/27/14 
Team/project: 
Overall team/project aim: Increase percentage of contraceptive prescriptions written for 15-25 year olds 
that are LARC methods from 6% to 20% over 12 weeks 
 
Overall population: clinic providers Test population: Same 
What is the objective of the test? 




Briefly describe the test: 
LARC project site provider opinion survey administered to participants 
Initial education and introduction of toolkit to providers and staff 
 
How will you know that the change is an improvement? 
Provider and staff feedback initially, a change in % of LARC prescriptions overall 
 
What driver does the change impact? 
Provider disclosure of LARC methods 
 
What do you predict will happen? 
Initial resistance to “anything new.” May find that disclosure changes as a result of introductory session, 
new resources, peer and leadership pressure to favor LARC methods 
 
Plan for change or test:  who, what, when, where (use back for more detail) 
1.5 hour meeting with all providers and staff at clinic site. Introductory presentation outlining the problem 












Test start date:  Target test completion date: 
 




(who) When Where 











3. Site director and medical director present 







Plan for collection of data:  (see Data Collection Plan form) 
 
Administered LARC project site provider opinion survey prior to beginning presentation to assess 
attendees’ attitudes about LARC prior to the intervention 
 
DO:  Test the changes. 
 
Was the cycle carried out as planned? 
Presentation and introduction of toolkit was carried out as planned 
Responses were less enthusiastic than anticipated-very few questions asked, when EBPI project leader 
asked what components of the toolkit attendees could picture themselves using one provider said “I just 
need time to digest this,” and no one else responded. 
Thoughts-may have given fewer resources in toolkit 
 
Medical director stated during the roll-out meeting that he wanted the scripting limited to providers and 
nurses for now due to “medico-legal concerns.” EBPI project leader reiterated that the goal was for no 
individual’s bias to create a barrier to the patient’s method choice. 
 
Record data and observations. 
 
What did you observe that was not part of our plan? 
 
Agency overseeing clinic held mandatory staff in-service on STI on 4/23/14. This program included a 
presentation on adolescents and LARC which reinforced the material presented on Monday. However, 
this also replaced the providers’ administrative time and was cited as the reason they did not look 
through the toolkit this week (per EBPI project liaison) 
 
STUDY:   
Did the results match your predictions? 
 
Presentation response was less enthusiastic than anticipated 




Compare the result of your test to your previous performance: 
 
What did you learn? 
 
May be that this group was less enthusiastic due to being asked to “do” something with the material 
rather than just opening discussion about LARC 
 
ACT:  Decide to Adopt, Adapt, or Abandon. 
             
Adapt:  Improve the change and continue testing plan. 
Plans/changes for next test: Consider pulling out pieces of toolkit to post in relevant locations in 
clinic. Will f/u with EBPI project liaison and site director about this. 
 
Adopt:  Select changes to implement on a larger scale and develop an implementation plan and 
plan for sustainability 
 








Cycle: 2  Date of test: 4/28/14-
5/11/14 
Team/project: 
Overall team/project aim: Increase percentage of contraceptive prescriptions written for 15-25 year olds 
that are LARC methods from 6% to 20% over 12 weeks 
 
Overall population: clinic providers Test population: Same 
What is the objective of the test? 




Briefly describe the test: 
Participant verbal feedback was that they had not used the toolkit and that their habits had not changed. 
Continue toolkit utilization and post prescribing algorithms in prominent places in the clinic. Note whether 
placing color algorithms where contraceptives are accessed increases utilization of prescribing algorithms 
by providers 
 
How will you know that the change is an improvement? 
Provider and staff feedback initially, a change in % of LARC prescriptions overall 
 
What driver does the change impact? 
Provider disclosure of LARC methods 
 
What do you predict will happen? 
Seeing LARC algorithm when accessing other contraceptive methods from contraceptive storage area 
will prompt participants to remember the project and counsel about LARC methods 
 




Test start date:  Target test completion date: 
 




(who) When Where 
1. Continue utilization of toolkit 
 






2.Post algorithms in prominent places 
 
Site director 4/28/14-5/6/14 clinic 
Plan for collection of data:  (see Data Collection Plan form) 
 
Email communication with EBPI project liaison 
 
DO:  Test the changes. 
 
Was the cycle carried out as planned? 
No- EBPI project liaison indicated that there was no discussion among providers about toolkit or LARCs 
this week and they “did not have time” to look at toolkit. 
 
Record data and observations. 
 
 




STUDY:   
Did the results match your predictions? 
 
No.  Providers still are not utilizing the toolkit, but may be utilizing the posted algorithms. Providers and 
staff are responsive to EBPI project leader’s presence as demonstrated by their verbal engagement 
when the EBPI project leader is on site.  
 
Compare the result of your test to your previous performance: 
 
No measurable result, participants still lacking the enthusiasm that was anticipated.  
 
What did you learn? 
Clinicians will need additional intervention to affect change 
 
ACT:  Decide to Adopt, Adapt, or Abandon. 
             
Adapt:  Improve the change and continue testing plan. 
Plans/changes for next test: 
 
Adopt:  Select changes to implement on a larger scale and develop an implementation plan and 
plan for sustainability – Per discussion with site director, will plan more “face time” from EBPI 
project leader. Algorithms and reminder notes strategically placed, biweekly emails to EBPI 
project liaison 
 









Cycle: 3 Date of test: 5/12/14-
5/18/14 
Team/project: 
Overall team/project aim: Increase percentage of contraceptive prescriptions written for 15-25 year olds 
that are LARC methods from 6% to 20% over 12 weeks 
 
Overall population: clinic providers Test population: Same 
What is the objective of the test? 
Continue use of prominently placed algorithms, increase “face time” between project leader and 




Briefly describe the test: 
Participant verbal feedback was that they had not used the toolkit and that their habits had not changed-
this remains unchanged from last week. However, participants acknowledged presence of algorithms. 
EBPI project leader noticed that participants are eager to talk, but do not utilize the toolkits and have 
not used the “parking lot” which is a notebook in the break room where participants can give anonymous 
feedback about the EBPI project.  
 
How will you know that the change is an improvement? 
Participants will increase percentage of LARC methods prescribed. 
 
What driver does the change impact? 
Provider disclosure and prescribing of LARC methods 
 
What do you predict will happen? 
Anticipate that the EBPI project leader’s presence will keep EBPI project in participants’ minds and 
help to clarify misperceptions verbally through organically occurring conversation since participants are 
not using toolkits. 
 
Plan for change or test:  who, what, when, where (use back for more detail) 
Continue to encourage use of toolkit, increase participant awareness of toolkit by posting algorithms in 
prominent places and increasing face time with EBPI project coordinator to twice weekly. 
PLAN 
 











(who) When Where 








Continue choice project LARC insertion 
algorithms in prominent locations 




3.increase on-site presence of EBPI 








Plan for collection of data:  (see Data Collection Plan form) 
 
Weekly visit to site and weekly email communication with EBPI project liaison 
 
DO:  Test the changes. 
 




Record data and observations. 
 
What did you observe that was not part of our plan? 
 
One clinician uses a different insertion algorithm and looks it up online each time she wants to utilize it.  
This algorithm is from reproductiveaccess.org 
 
STUDY:   




Compare the result of your test to your previous performance: 
 
What did you learn? 
Clinicians will continue to need additional intervention to affect change.  EBPI project leader will 
examine contraceptive algorithms at reproductiveaccess.org to determine consistency with toolkit 
algorithms. 
 
ACT:  Decide to Adopt, Adapt, or Abandon. 
             
Adapt:  Improve the change and continue testing plan. 
Plans/changes for next test: examine contraceptive algorithms at reproductiveaccess.org 
 
Adopt:  Select changes to implement on a larger scale and develop an implementation plan and 





project leader. Algorithms and reminder notes strategically placed, biweekly emails to lead 
clinician 
Abandon:  Discard this change idea and try a different one 
 
PDSA WORKSHEET 
Cycle: 4 Date of test: 5/19/14-
5/25/14 
Team/project: 
Overall team/project aim: Increase percentage of contraceptive prescriptions written for 15-25 year olds 
that are LARC methods from 6% to 20% over 12 weeks 
 
Overall population: clinic providers Test population: Same 
What is the objective of the test? 
Continue use of prominently placed algorithms, increased “face time” with EBPI project coordinator to 
twice weekly, add “quick start algorithm” and “switching contraceptive methods” algorithm from the 
Reproductive Health Access Project (http://www.reproductiveaccess.org/) because one of the providers 
shared that she refers to these algorithms online as needed because she had become accustomed to 
doing so prior to the introduction of the toolkit. These algorithms were not added to the provider resource 




Briefly describe the test: 
 
Reproductive Access algorithms were added to provider workspace as one provider is using these 
preferentially already and the information is consistent with the toolkit and the goals of the EBPI project.  
 
How will you know that the change is an improvement? 
Participants will prescribe an increased percentage of LARC methods 
 
What driver does the change impact? 
Provider disclosure and prescribing of LARC methods 
 
What do you predict will happen? 
Seeing LARC algorithm when accessing other contraceptive methods from contraceptive storage area 
will prompt participants to remember the EBPI project and counsel about LARC methods-this remains 
unchanged. 
Anticipate that EBPI project leader presence will keep EBPI project in participants’ minds and help to 
clarify misperceptions verbally through organically occurring conversation since participants are not using 






online with each use) will increase the potential for LARC disclosure/prescribing at least for the one 
provider who prefers those algorithms.  
 
Plan for change or test:  who, what, when, where (use back for more detail) 





Test start date: Target test completion date: 
 




(who) When Where 
1. Continue utilization of toolkit 
 
Providers 5/15/14-5/21/14 clinic 
2. 
Continue choice project LARC insertion 
algorithms in prominent locations 
Site director 5/15/14-5/21/14 clinic 
3.increase on-site presence of EBPI 











Plan for collection of data:  (see Data Collection Plan form) 
 
Email communication with lead clinician, visit to site. Record prescribing data for first month (collected by 
clinic nurse) 
 
DO:  Test the changes. 
 
Was the cycle carried out as planned? 
Yes 
 
Record data and observations. 
 
Providers and staff responded positively to increased face-time. Began to spontaneously socialize with 
the EBPI project leader and discuss their beliefs and prescribing habits more freely.  
 
What did you observe that was not part of our plan? 
 
Providers are still not utilizing the toolkit. Verbally they indicate that they perceive themselves already 
prescribing LARC methods at every opportunity and don’t see a need to increase.  
At this site providers order DMPA for a year at each annual exam and the follow-up visits ( every 11-15 
weeks) are nurse visits in which the patient does not see a provider. 
 
STUDY:   




No, prediction was that providers would be more enthusiastic about change once they had motivating 
information. 
 
Compare the result of your test to your previous performance: 
 
Providers are more verbally engaged with the EBPI project leader, but “buy-in” remains questionable. 
 
 
What did you learn? 
Face time is critical to establish the EBPI project, but cannot be part of the sustainability plan.  
Clinicians will need additional intervention to affect change 
 
 
ACT:  Decide to Adopt, Adapt, or Abandon. 
             
Adapt:  Improve the change and continue testing plan. 
Plans/changes for next test: 
Add: training for nurses who administer 3 of the 4 DMPA visits per patient per year.  
 
 
Adopt:  Select changes to implement on a larger scale and develop an implementation plan and 
plan for sustainability – Per discussion with site director, will continue more “face time” from the 
EBPI project leader. Algorithms and reminder notes strategically placed, biweekly emails to 
lead clinician.  
 









Cycle: 5 Date of test: 5/26/14-
6/8/14 
Team/project: 
Overall team/project aim: Increase percentage of contraceptive prescriptions written for 15-25 year olds 
that are LARC methods from 6% to 20% over 12 weeks 
 
Overall population: clinic providers Test population: Same 
What is the objective of the test? 
Work with nursing staff (3 nurses) to deliver LARC information at follow-up DMPA injections. At this site 
providers order DMPA for a year at each annual exam and the follow-up visits (every 11-13 weeks) are 




Briefly describe the test: 
Train RNs and LPNs to counsel at DMPA injection visits using same information from initial training 
tailored to the RN/LPN role at this site and focusing on LARC as an alternative to DMPA. 
 
How will you know that the change is an improvement? 
Participants will increase the percentage of LARC prescriptions 
 
What driver does the change impact? 
Provider disclosure and prescribing of LARC methods 
 
What do you predict will happen? 
 
RNs and LPNs will use DMPA injection visits to counsel about LARC. Patients will then request LARC 
which will be measured by an increase in LARC prescriptions. 
 
Plan for change or test:  who, what, when, where (use back for more detail) 
 
Train RNs and LPNs to counsel at DMPA injection visits using same information from initial training 
tailored to the RN/LPN role at this site and focusing on LARC as an alternative to DMPA. 
 
PLAN 











(who) When Where 
1. Continue utilization of toolkit 
 
 Providers 5/15/14-5/21/14 clinic 
2. Continue choice project LARC insertion 
algorithms in prominent locations 
Site director 5/15/14-5/21/14 clinic 
3.increase on-site presence of EBPI 











5. Train RNs and LPNs to counsel about 
LARCs at DMPA visits. 
 






Plan for collection of data:  (see Data Collection Plan form) 
 
Email communication with lead clinician, visit to site. Record prescribing data (collected by nurse) 
 
DO:  Test the changes. 
 
Was the cycle carried out as planned? 
No, two of the three nurses were out sick during the scheduled time, so EBPI project leader met with 
each nurse individually over several weeks. 
 
 
Record data and observations. 
 
All three nurses verbally expressed interest in the EBPI project and in educating patients at f/u DMPA 
visits.  Two nurses stated that the information was not a change from how they already counseled at 
these visits.  One nurse stated that she had not previously known that a LARC could be initiated prior to 
the next scheduled DMPA injection. 
 
What did you observe that was not part of our plan? 
 
Providers are still not utilizing the toolkit. Verbally they indicate that they perceive themselves already 




STUDY:   
Did the results match your predictions? 
 
Fewer nurses were educated than planned in first week so cycle was extended to two weeks.  
 




What did you learn? 
Need to continue to be available for face time and follow up as needed to adapt to clinic schedule and 
staffing.  
 
ACT:  Decide to Adopt, Adapt, or Abandon. 
             
Adapt:  Improve the change and continue testing plan. 
Plans/changes for next test: Share results from first 4 weeks of EBPI project, Give positive 
feedback about changes noted in hopes that this will increased awareness of and enthusiasm 
about EBPI project. 
 
Adopt:  continue training anyone who administers DMPA at this site.  Currently all such 
personnel have been trained. 
 









Cycle: 6 Date of test: 6/9/14-
6/29/14 
Team/project: 
Overall team/project aim: Increase percentage of contraceptive prescriptions written for 15-25 year olds 
that are LARC methods from 6% to 20% over 12 weeks 
 
Overall population: clinic providers Test population: Same 
What is the objective of the test? 
Continue as above from previous weeks.  Added feedback that LARC prescribing had increased for 
adolescents and young women and posed two questions to prescribers by email. Questions were 
developed by the site director based on her knowledge of the individuals involved: 
1) Why do you think LARC prescribing has increased? 




Briefly describe the test: 
Continue as above from previous weeks. Added feedback that LARC prescribing had increased for 
adolescents and young women and posed two questions to prescribers by email: 
3) Why do you think LARC prescribing has increased? 
4) What have you done to contribute to the increase? 
Continue as above from previous weeks.  
 
How will you know that the change is an improvement? 
Participants will prescribe an increased percentage of LARC methods 
 
What driver does the change impact? 
Provider disclosure and prescribing of LARC methods 
 
What do you predict will happen? 
Positive feedback about first month’s data may renew interest in the EBPI project. Reflecting on 
questions posed may increase provider “buy in” for the EBPI project. 
 
Plan for change or test:  who, what, when, where (use back for more detail) 
 











Test start date:  Target test completion date: 
 




(who) When Where 
1. Utilization of toolkit 
 
Providers 5/15/14-5/21/14 clinic 
2. 
Continue choice project LARC insertion 
algorithms in prominent locations 
Site director 5/15/14-5/21/14 clinic 
3.increase on-site presence of EBPI 












Give LARC prescribing feedback to 
providers and pose questions about why 











Plan for collection of data:  (see Data Collection Plan form) 
 
Email communication with lead clinician, visit to site. Record prescribing data (collected by nurse) 
 
DO:  Test the changes. 
 
Was the cycle carried out as planned? 
Yes 
 
Record data and observations. 
 
One provider she did alter her counseling about LARC to discuss LARC methods first. Other providers 
responded verbally and by email that they did not know why a change was observed, that they did not do 
anything to affect the change, and that it may have been due to chance.  One participant wrote, “I’m not 
sure why there has been a difference. Maybe everyone feels more comfortable discussing LARCs with 
our patients since we received the education from you? Or maybe it’s a coincidence? It’s hard to say. But 
it’s a good thing! I think the only thing that has changed with my practice is that when I list contraceptive 
options; I start with the LARCs and work my way down. I used to start with the pills because that’s what 
most patients are most familiar with.“ 
STUDY:   




It was predicted that providers would be able to verbalize ways they had contributed to change and that 
awareness of a positive change would provide motivation to continue to improve.  One provider was able 
to articulate a way she had changed and possibly contributed to the improvement.  The other two 
providers wrote that they did not perceive a need for change and thought the observed change was due 
to chance. 
 
Compare the result of your test to your previous performance: 
 
What did you learn? 
Clinicians continue to need additional intervention to affect change 
 
 
ACT:  Decide to Adopt, Adapt, or Abandon. 
             
Adapt:  Improve the change and continue testing plan. 
Plans/changes for next test: 
 
Adopt:  Continue as is, Assemble data from the second four weeks of the EBPI project and 
continue to solicit feedback from participants. 
 













Overall team/project aim: Increase percentage of contraceptive prescriptions written for 15-25 year olds 
that are LARC methods from 6% to 20% over 12 weeks 
 
Overall population: clinic providers Test population: Same 
What is the objective of the test? 
The plan was to compile and evaluate data from the second 4 weeks of the EBPI project and 
present these to participants to generate continuing momentum and possibly increase buy-in for 
the EBPI project.  During data compilation the EBPI project leader realized that clinicians 
were generating a new DMPA prescription with every injection rather than generating one 
prescription yearly with refills.  Because data was being counted based on the number of 
prescriptions generated for each method type, this was essentially quadrupling the number of 
prescriptions for DMPA.  The EBPI project leader and the data collector reexamined the 
numbers, altering the criteria to reflect prescriptions generated during a visit with a clinician 
only. At this point overall data for the entire EBPI project period was shared with each 
participant.  At the end of cycle 7 participants were once again congratulated for the positive 
change in prescribing for women aged 15-25 and were asked to complete the LARC project 
site provider opinion survey (identical to the one given before the initial teaching) in order to 




Briefly describe the test: 
Continue as above from previous weeks 
 
How will you know that the change is an improvement? 
Participants will prescribe more LARC methods 
 
What driver does the change impact? 
Provider disclosure and prescribing of LARC methods 
 
What do you predict will happen? 
Positive data will increase buy-in.  
 
Plan for change or test:  who, what, when, where (use back for more detail) 
 








Test start date:  Target test completion date: 
 




(who) When Where 
1. Utilization of toolkit 
 
Providers 5/15/14-5/21/14 clinic 
2. Continue choice project LARC insertion 
algorithms in prominent locations 
Site director 5/15/14-5/21/14 clinic 
3.increase on-site presence of project 











5. Give LARC prescribing feedback to 
providers and pose questions about why 








June/July 2014 clinic 
7. Share overall project outcomes EBPI project 
leader and all 
participants 
July, 2014  
 
Plan for collection of data:  (see Data Collection Plan form) 
 
Email communication with lead clinician, visit to site. Record prescribing data (collected by nurse) 
 
DO:  Test the changes. 
 
Was the cycle carried out as planned? 
Yes 
 
Record data and observations. 
 
What did you observe that was not part of our plan? 
Providers are still not utilizing the written materials. Verbally participants indicate that they perceive 
themselves already prescribing LARC methods at every opportunity and don’t see a need to increase.  
 
Leadership has not responded to inquiry about EBPI project alteration and continuation. 
 
See above 
STUDY:   




Predicted that leadership would be more eager to adapt and continue EBPI project due to funding that 
is dependent on LARC prescribing numbers and eagerness to be a leader in the public health 
community. Did not anticipate that funding cuts from other sources would alter staffing during this cycle 
and going forward thereby distracting the leadership with other issues.  
 
Compare the result of your test to your previous performance: 
 
What did you learn? 
Face time is critical to establish the EBPI project, but cannot be part of the sustainability plan.  
Clinicians will need additional intervention to affect change 
 
 
ACT:  Decide to Adopt, Adapt, or Abandon. 
             
Adapt:  Improve the change and continue testing plan. 
Plans/changes for next test: 
 
Adopt:  Collect final data for dissemination  
 











CHOICE LARC Insertion Timing Algorithm 
 
Advanced Practitioner Resources: Provision Guides 
modification date: August 1, 2013 
content: LARC Insertion Timing Algorithm 
  
Overview 
This document describes the algorithm used by CHOICE in determining LARC insertion 
timing.  
 
 
